| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-04-21 | BiogenIdec (USA - MA) Amunix (USA - CA) | fully-recombinant Factor VIII products | hemophilia | licensing |
Hematologic diseases - Genetic diseases - Rare diseases | Exercise of an option agreement |
| 2014-04-17 | Medivation (USA - MA) | member of the board of directors | nomination | Cancer - Oncology | Nomination | |
| 2014-04-16 | The Lead Discovery Center (LDC) (Germany) Daiichi Sankyo (Japan) | collaboration |
Cancer - Oncology - Cardiovascular diseases - Metabolic diseases | Collaboration agreement | ||
| 2014-04-15 | Cellmid (Australia) Biotecnol (UK) | midkine (MK) Tribodies™ | Cancer - Oncology | Establishment of a new subsidiary in the EU | ||
| 2014-04-15 | Mucosis (The Netherlands) Changchun Bcht Biotechnology (China) | SynGEM® prefusion F vaccine candidate and Mimopath® platform | prevention of Respiratory Syncytial Virus (RSV) infection | Infectious diseases | Licensing agreement | |
| 2014-04-14 | Effimune (France) Inserm (France) | Transplantation | Collaboration agreement | |||
| 2014-04-11 | PolyTherics (UK) MacroGenics (USA - MD) | ThioBridge™ antibody drug conjugate (ADC) | Technology - Services | Collaboration agreement | ||
| 2014-04-10 | Valneva (France - Austria) Adimmune Corporation (Taiwan) | vaccine for the prevention of Japanese encephalitis (IXIARO®) | Japanese encephalitis | licensing |
Infectious diseases | Licensing agreement |
| 2014-04-09 | Spero Therapeutics (USA) Roche (Switzerland) | Infectious diseases | Collaboration agreement | |||
| 2014-04-09 | DBV Technologies (France) CEA (France) | characterization of the epigenetic modifications induced by DBV\'s proprietary epicutaneous immunotherapy (EPIT™) | R&D collaboration |
R&D agreement | ||
| 2014-04-08 | Theradiag (France) - CNRS (France) | microRNA signatures for diagnostics and theranostics tools | rheumatoid arthritis | collaboration |
Diagnostic - Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Collaboration agreement |
| 2014-04-08 | Medigene (Germany) Kora Healthcare (Ireland) | Veregen® ointment (made from the extract of green tea leaves - catechins) | genital warts | commercialisation |
Infectious diseases - Gynecology | Commercialisation agreement |
| 2014-04-08 | Atara Biotherapeutics (USA - CA) | director | nomination | Cancer - Oncology - Kidney diseases - Renal diseases | Nomination | |
| 2014-04-07 | AstraZeneca (UK) Starpharma (Australia) | oncology molecules based on Starpharma’s dendrimer technology | undisclosed cancers | R&D |
Cancer - Oncology | R&D agreement |
| 2014-04-07 | MRC Technology (UK) Chinese Academy of Science (China) | innovative drugable targets | undisclosed | R&D |
undisclosed | R&D agreement |
| 2014-04-03 | Swedish Orphan Biovitrum-Sobi (Sweden) Tigenix (Belgium) | ChondroCelect® (characterised cultured chondrocytes derived from the patient’s own cartilage and used for autologous chondrocyte implantation) | repair of single symptomatic cartilage defects of the femoral condyle of the knee (International Cartilage Repair Society [ICRS] grade III or IV) in adults | licensing |
Regenerative medicine - Bone diseases | Licensing agreement |
| 2014-04-03 | Integragen (France) Pfizer (USA - NY) | molecular signature for hepatocellular carcinoma | hepatocellular carcinoma | Cancer - Oncology | Services contract | |
| 2014-04-03 | UCB (Belgium) Weill Cornell Medical College (USA - NY) | R&D |
Bone diseases - Metabolic diseases | R&D agreement | ||
| 2014-04-03 | Merck Serono (Germany) Auxogyn (USA - CA) | Early Embryo Viability Assessment (Eeva®) Test | licensing |
Women health | Licensing agreement | |
| 2014-04-02 | Evotec (Germany) Debiopharm (Switzerland) | solid tumors and leukemias with defined genetic alterations | R&D |
Cancer - Oncology | R&D agreement |
